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Abstract Glioblastoma multiforme (GBM) is an incurable
form of brain cancer with a very poor prognosis. Because of
its highly invasive nature, it is impossible to remove all
tumor cells during surgical resection, making relapse inevi-
table. Further research into the regulatory mechanism un-
derpinning GBM pathogenesis is therefore warranted, and
over the past decade, there has been an increased focus on
the functional role of microRNA (miRNA). This systematic
review aims to present a comprehensive overview of all the
available literature on the expression profiles and function
of miRNA in GBM. Here, we have reviewed 163 papers and
identified 253 upregulated, 95 downregulated, and 17 dis-
puted miRNAs with respect to expression levels; 85 % of
these miRNAs have not yet been functionally characterized.
A focus in this study has been 26 interesting miRNAs
involved in the mesenchymal mode of migration and inva-
sion, demonstrating the importance of miRNAs in the con-
text of the cellular niche. Both oncogenic and tumor-
suppressive miRNAs were found to affect target genes in-
volved in cell migration, cytoskeletal rearrangement, inva-
siveness, and angiogenesis. Clearly, the distinct functional
properties of these miRNAs need further investigation and
might hold a great potential in future molecular therapies
targeting GBM.
Keywords MicroRNA . Glioblastoma . Glioma .
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Introduction
Glioblastoma multiforme (GBM) is a highly prevalent, in-
curable form of cancer emanating from the brain, account-
ing for 12–15 % of all brain tumors and approximately 70 %
of all diagnosed gliomas [1, 2]. Among the WHO grades of
astrocytoma, GBM is classified as being the most pro-
gressed and severe (grade IV). It is characterized by an
extremely poor prognosis, reflected in a mean survival rate
of only 3.3 % at 2 years and 1.2 % at 3 years [3, 4]. While
GBM rarely metastasizes, it characteristically grows by
infiltrating the surrounding brain tissue [5]. Because of this
highly invasive nature, it is impossible to completely re-
move all tumor cells during surgical resection [6].
Today, treatment of GBM is primarily through tumor
resection and subsequent radio- and chemotherapy, typically
alkylating agents, e.g., temozolomide [7, 8]. Despite inten-
sive efforts to improve current treatment and explore new
therapeutic targets, pivotal clinical improvement has
remained absent during the last decade [7, 9]. Other forms
of treatment, such as photodynamic therapy, based on pho-
tooxidative reactions and accumulation of photo sensitizers
in tumor tissue, can be used to facilitate tumor resection and
target cell proliferation [10]. Molecular phenotyping of
GBM is opening up the potential for molecularly targeted
therapies. These can take the form of targeting specific
components of oncogenic pathways, e.g., through delivery
Electronic supplementary material The online version of this article
(doi:10.1007/s12035-012-8349-7) contains supplementary material,
which is available to authorized users.
Heidi G. Møller, Andreas P. Rasmussen, Hjalte H. Andersen, and
Kasper B. Johnsen contributed equally in writing this review paper.
H. G. Møller :A. P. Rasmussen :H. H. Andersen :K. B. Johnsen :
M. Henriksen :M. Duroux (*)
Department of Biomedicine,
Institute for Medicine and Health Technology, Aalborg University,
Fredrik Bajers Vej 3B,
9220 Aalborg Øst, Denmark
e-mail: megd@hst.aau.dk
Mol Neurobiol (2013) 47:131–144
DOI 10.1007/s12035-012-8349-7
of a therapeutic gene or microRNA (miRNA) [9, 11–13].
Several miRNAs are differentially expressed in a variety of
malignancies compared to corresponding healthy tissue.
Some of these miRNAs have been shown to modulate
oncogenes and tumor suppressors, as is the case for GBM.
Therefore, miRNAs could hold a great potential in the future
treatment of this disease.
Biogenesis of miRNA
In order to understand the context of miRNA in GBM
pathology, we highlight here the essential steps in the bio-
genesis of miRNAs and the effects they exert on their
downstream functional targets (Fig. 1). miRNAs are small
RNA molecules of approximately 20–23 nucleotides, which
have been identified as important regulators of mRNA
translation [14]. The biogenesis of miRNA starts with tran-
scription of miRNA genes by RNA polymerase II/III (Pol II/
III), generating a primary transcript (pri-miRNA) that is
both capped and polyadenylated. The transcript folds into
a stem-loop structure via intramolecular base-pairing [14].
The stem-loop structure is cleaved to pre-miRNA by the
Drosha/DGCR8 complex and actively transported out of the
nucleus by Exportin-5 in the presence of Ran-GTP cofactor
[15]. In the cytoplasm, the RNAseIII enzyme Dicer makes
the final cleavage to a double-stranded miRNA, of which
one strand is incorporated into the RNA-induced silencing
complex (RISC), the cytoplasmic effector machine for
miRNA. The other strand is degraded [16]. RISC is com-
prised of Dicer, the double-stranded RNA binding factor
(TRBP) and Argonaut protein 2 (Ago2). The posttranscrip-
tional RNA silencing is mediated through complementary
binding of miRNAwithin RISC to the mRNA 3′ untranslat-
ed region, resulting in mRNA cleavage, translational inhi-
bition, or mRNA decay [17]. This mRNA interference
results in a decreased level of encoded proteins, hereby
affecting an array of cellular processes, e.g., proliferation,
migration, and apoptosis[18]. A new and less-studied fate of
miRNAs is the selective excretion via lipoproteins or micro-
vesicles, possibly functioning as a way of intercellular com-
munication [19, 20].
Studies of microRNA in Glioblastoma Multiforme
The scope of this paper is to provide the most up-to-date
review of the current literature pertaining to miRNA studies
in GBM. The first two papers investigating miRNA expres-
sion profiles in GBM were published almost simultaneously
in 2005 [21, 22]. Ciafrè et al. demonstrated aberrant expres-
sion levels of numerous miRNAs when comparing GBM
tumor samples to normal brain tissue [22]. While also
analyzing miRNA expression levels, Chan et al. [21] were
the first to investigate the functional properties of a single
miRNA in GBM cell lines. They found that inhibition of
miR-21 resulted in significantly increased apoptosis and,
therefore, hypothesized that miR-21 could function as a
micro-oncogene [21]. Since these early findings, the number
of studies published on this subject has steadily increased,
elucidating numerous interesting miRNA-mediated mecha-
nisms in the tumorigenesis of GBM.
To obtain a comprehensive overview of the current
knowledge on miRNA expression and function in GBM,
all available literature on the subject was reviewed. A Med-
line database search on: “microRNA and Glioblastoma”
plus “microRNA and Glioma”1 was performed (date of
search entry: April 20, 2012). The results contained a total
of 256 papers, of which 163 were found relevant, based on
the title and abstract content. The 163 papers were reviewed,
102 of them met the inclusion criteria, which encompassed
studies investigating expression levels of miRNAs in GBM
tumor samples compared to normal brain tissue, and/or
studies exploring the functional properties of selected miR-
NAs in GBM cell lines. Of the remaining 61 papers, 34 were
studies primarily focusing on diagnostics, delivery, and
prognostics and were categorized as editor’s notes or gener-
ally not the scope of the topic. Twenty-seven papers were
reviews and review-like articles, discussing the role of
miRNA in GBM. Clearly, none of the 27 reviews were
highly systematic in their approach; primarily, they de-
scribed few well-known and reviewed miRNAs. All rele-
vant material extracted from the 102 papers that were
reviewed has been presented in the form of a supplementary
table (Supplementary Table 1). The content of this supple-
mentary table provides the foundation for the material dis-
cussed in the following sections of the paper. Each section
attempts to highlight the population of upregulated, down-
regulated, and novel miRNAs. Emphasis on the promising
therapeutic potential of specific miRNAs is presented with a
focus on the mesenchymal mode of migration and invasion
(MMMI) in GBM.
MicroRNAs Upregulated in Glioblastoma Multiforme
Based solely on the literature contained in this review, it
appears that the most common dysregulation of miRNA in
GBM is overexpression, thus, 256 miRNAs were found
significantly overexpressed (Supplementary Table 1). Few
of these, for example miR-17, miR-21, miR-93, and miR-
221/222, have been intensively investigated with respect to
1 Search typed: “(microRNA AND Glioblastoma) OR (microRNA
AND Glioma)”
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both expression and functionality, but the functional prop-
erties of the vast majority remains completely unknown.
Table 1 display all miRNAs that were found upregulated
in greater than or equal to five studies and/or functionally
investigated, with emphasis on luciferase-validated targets,
in at least one study. In the following sections, miRNAs that
are particularly interesting, extensively investigated, or nov-
el are discussed.
miR-10b
Since its first investigation by Ciafrè et al., overexpression
of miR-10b in GBM has been confirmed in eight studies
[22–29]. A significant WHO grade specific correlation of its
overexpression has been observed, thus implying the
pertinent role of miR-10b in GBM grade progression [28,
29]. Expression levels of urokinase receptor (uPAR) and
Ras homolog gene family member C (RhoC) were found
to be directly proportional to that of miR-10b, thereby
enhancing the invasive capabilities of high-grade glioma
[28]. Recently, a negative regulator of uPAR and RhoC,
HOXD10, was confirmed as a direct target of miR-10b [29].
miR-17~92-cluster
The expression of the miR-17∼92-cluster (comprising miR-
17-3p, miR-17-5p, miR-18a, miR-19a, miR-19b, miR-20a,
and miR-92a) is upregulated in GBM tumor samples and
cell lines [24–26, 30–34]. The miR-17∼92-cluster has been
shown to possess a variety of tumorigenic properties,
Fig. 1 The linear biogenesis of
miRNA. miRNA biogenesis
involves transcription of pri-
miRNA by RNA polymerase II/
III, cleavage by the Drosha-
DGCR8 complex to pre-
miRNA, followed by export to
the cytoplasm by Exportin-5 in
the presence of Ran-GTP co-
factor. In the cytoplasm, pre-
miRNA is cleaved by the Dicer-
TRBP complex to a miRNA
duplex, which is unwound to a
guide strand that is bound to
Ago2 and incorporated into the
RISC, and a passenger strand,
which is degraded. Ultimately,
miRNA binding to target
mRNAs results in mRNA target
cleavage, translational repres-
sion, or mRNA decay. A more
novel fate of the miRNAs is the
selective secretion via microve-
sicles or exosomes
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Table 1 Upregulated miRNAs and their functional role in GBM
miRNA Targets Functional role when 1:
overexpressed, 2: underexpressed
Reference
Hsa-mir-9 CAMTA1 [23, 24, 30–32]
Hsa-mir-9* CAMTA1 2: Proliferation↓, Stemness↓ [25, 32]
Hsa-mir-10ba HOXD10d 1:Invasiveness↑ [22–29]
2: Invasiveness↓
Hsa-mir-15b CCNE1 1:Proliferation↑ [23–25, 31, 35, 100]
2: Proliferation↓
Hsa-mir-16 [24, 25, 30, 31, 36]
Hsa-mir-17a POLD2, TGFβ-RIIb,
CTGF, CAMTA1
1:Angiogenesis↑, Growth↑ [24–26, 30–34]
2: Viability↓, Apoptosis↑, Proliferation↓
Hsa-mir-18aa Smad4, CTGF 1:Angiogenesis↑, Growth↑ [25, 33, 34]
2: Viability↓, Apoptosis↑, Proliferation↓







1:Invasiveness↑ [21–28, 30, 31, 35–55]
2: Invasiveness↓, Apoptosis↑, Viability↓,
Proliferation↓, In vivo tumor volume↓,
Chemosensitivity↑
Hsa-mir-23a [22–25, 35, 37, 52]
Hsa-mir-25c Mdm2, TSC1 1:In vivo tumor volume↓ [22–26, 30, 101]
Hsa-mir-26ac PTEN 1:In vivo tumor volume↑ [23, 25, 37]
Hsa-mir-27a WEE1 [23, 25, 52]
Hsa-mir-30ec IκBαd 1:Invasiveness↑, Proliferation↑,
Angiogenesis↑, In vivo tumor volume↑
[25, 96]
2: Invasiveness↓, Proliferation↓,
Angiogenesis↓, In vivo tumor volume↓
Hsa-mir-92 a CTGF 2: Viability↓, Proliferation↓ [25, 26, 33, 34]
Hsa-mir-93ac Integrin-β8d 1:Angiogenesis↑, Proliferation↑,
In vivo tumor volume↑
[23, 24, 26, 56]
Hsa-mir-106b [23–26, 28, 52]
Hsa-mir-125b Bmf 1:Invasiveness↑, Apoptosis↓, Proliferation↑ [25, 97, 102, 103]
Hsa-mir-146ac Notch1 1:Proliferation↓, In vivo tumor volume↓, Migration↓ [24, 25, 104]
Hsa-mir-155 2: Viability↓, Apoptosis↑, Chemosensitivity↑ [24–26, 31, 36, 105]
Hsa-mir-182 [23–26, 37, 106]
Hsa-mir-183 [23, 25, 26, 106, 107]
Hsa-mir-210 [25, 26, 30, 31, 36]
Hsa-mir-221c P27, Aktd, PUMA, P57, PTPμd 1:Proliferation↑, Invasiveness↑, in vivo
tumor volume↑, Apoptosis↓, Migration↑
[22, 35, 52, 53, 98, 108–113]
2: Proliferation↓, Apoptosis↑, in vivo tumor volume↓
Hsa-mir-222c Akt, PUMA, P57, PTPμd 1:Proliferation↑, Invasiveness↑, In vivo tumor
volume↑, Apoptosis↓, Migration↑
[22, 35, 52, 98, 109–113]
2: Proliferation↓, Apoptosis↑, in vivo tumor volume↓
Hsa-mir-335bc Daam1d 1:Viability↑, Invasiveness↑ [25, 59]
2: Apoptosis↑, Invasiveness↓, In vivo tumor volume↓
Hsa-mir-381bc LRRC4 1:Proliferation↑, In vivo tumor volume↑ [60]
2: Proliferation↓
miRNAs consistently upregulated in glioblastoma. The table presents miRNAs with observed effects upon their downregulation and their validated
targets. The cell lines in which the studies have been performed are presented. Only miRNAs that have been investigated in greater than or equal to five
studies and/or have a validated target are included in this table. The cell lines applied in the annotated studies can be found in Supplementary Table 1
aMentioned in the section “MicroRNAs Upregulated in Glioblastoma Multiforme”
bMentioned in the section “MicroRNAs Upregulated in Glioblastoma Multiforme with Limited Functional Characterization”
cMicroRNAs whose down regulation is shown to inhibit tumour growth in vivo
d Targets involved in the mesenchymal mode of migration and invasion
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mediated through direct targeting of antiproliferative
genes (TGFBRII, SMAD4, and CAMTA1) and regula-
tors of angiogenesis and DNA-repair (CTGF, and
POLD2). Hence, inhibition of specific miR-17∼92-clus-
ter members decreases viability and increases apoptosis
in vitro [30, 33, 34].
miR-21
Until now, the most extensively investigated miRNA is
miR-21, which is consistently reported to be overex-
pressed in GBM in a WHO-grade specific manner
[21–28, 30, 31, 35–55]. Forced downregulation of
miR-21 reduces the oncogenic potential of GBM cell
lines through inhibition of several cellular processes
involved in malignancy maintenance. Proliferation is
significantly reduced by cessation of miR-21 inhibition
on the target genes ANP32A, SMARCA4, PTEN,
SPRY2, and LRRFIP1 [35, 39, 46, 50]. This reduction
is also associated with a decrease in the protein levels
of key components of proliferation-linked signaling
pathways, e.g., NF-κB and Ras [46]. These results were
further substantiated by decreased tumor growth in im-
munodeficient mice [35, 43, 51]. miR-21 inhibition does
also result in significantly increased levels of caspases,
leading to an increase in apoptosis, mediated by de-
creased targeting of HNRPK, TAp63, and PDCD4 [40,
42, 51]. miR-21 affects invasion by decreasing the ex-
pression levels of RECK and TIMP3, which normally
retains the levels of MMPs [38, 40]. Furthermore, trans-
fection with antisense-miR-21 has been shown to sig-
nificantly increase GBM cell line sensitivity to both
radio- and chemotherapy [41, 44, 47, 48]. This aspect
of its function makes miR-21 of particular interest for
exploitation in molecular therapy [47].
miR-93
While several studies have proven that miR-93 is upre-
gulated in GBM [23, 24, 26], only one study has
investigated its functional properties [56]. Fang et al.
[57] used in vitro and in vivo studies to emphasize the
functional role of this miRNA in angiogenesis. Using
transfection, they further upregulated miR-93 in the
model cell line U87. Following co-culture with endo-
thelial cells, they observed increased endothelial cell
proliferation and tube formation. Integrin-β8, which
inhibits close association between tumor cells and en-
dothelial cells, was found to be a direct target of miR-
93. These results were then substantiated with in vivo
assays, showing highly increased blood vessel formation
in GBM xenograft tumors in mice, strongly validating
miR-93 as an angiogenic inducer [56].
MicroRNAs Upregulated in Glioblastoma Multiforme
with Limited Functional Characterization
The case with many studies is that trends are followed
around well-studied target genes in order to substantiate
and validate results. To date, the center of attention has been
pivotal around relatively few, well-investigated miRNAs,
such as miR-15b, miR-21, miR-221, and miR-222 [58].
However, research on novel miRNAs, e.g., miR-335 and
miR-381, has recently been published [59, 60]. miR-335
was upregulated in GBM and shown to increase prolifera-
tion and invasion in malignant astrocytoma, through direct
targeting of DAAM1. These effects were reversed by miR-
335 silencing [59, 61]. Another upregulated, novel miRNA,
miR-381, was shown to increase the level of proliferation
both in vitro and in xenograft mouse models. Through
direct targeting of leucine-rich repeat C4 (LRRC4), miR-
381 caused increased levels of phosphorylated MEK,
ERK, and AKT, thus, impacting several important compo-
nents of mitogenic signaling pathways [60]. Additionally,
miR-16, miR-23a, miR-106b, miR-182, miR-183, and
miR-210 were found to be consistently upregulated in greater
than or equal to five studies but remain completely uninves-
tigated with respect to functional properties (Table 1).
MicroRNAs Downregulated in GlioblastomaMultiforme
Throughout the reviewed literature, 95 miRNAs were
reported as downregulated in GBM, compared to normal
brain tissue (Supplementary Table 1). Of these, 28 were
reported as downregulated in greater than or equal to five
studies and/or functionally investigated, with emphasis on
luciferase-validated targets, in at least one study (shown in
Table 2). Interestingly, what one can infer is that miRNAs
that are consistently downregulated in GBM often appear to
possess anti-tumorigenic abilities (Table 2). Therefore, fur-
ther investigation of these miRNAs could generate knowl-
edge on valuable therapeutic targets. In the following
section, downregulated, well-investigated miRNAs are
highlighted. In conjunction with this, the novel miRNAs
are discussed.
miR-7
Seven studies published within the last 4 years have estab-
lished miR-7 as being downregulated in GBM [25, 27, 31,
62–65]. A study by Lages et al. found a decrease in miR-7
expression of 0.11 and 0.09 fold in GBM and oligodendro-
glioma, respectively, suggesting that miR-7 also has a key
role in tumors of non-astrocytic origin [31]. The first paper
to functionally characterize miR-7 in GBM was published in
2008 by Kefas et al. and utilized a luciferase reporter assay
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to establish EGFR, frequently amplified in GBM [66], and
IRS-2 as a direct targets of miR-7 [65]. Interestingly, the
same paper found that transfection with miR-7 led to a
decrease in phosphorylated Akt in a non EGFR-dependent
manner and reduced invasiveness in several GBM cell lines
[65]. More recently, it was shown that Focal Adhesion
Kinase (FAK) is also a direct target of miR-7 and that over-
expression of miR-7 resulted in decreased rates of both
Table 2 Downregulated miRNA and their functional role in GBM
miRNA Target Functional role when overexpressed Reference
Hsa-mir-7 FAK, EGFR, IRS2 Viability↓, Migration↓, Invasiveness↓,
Proliferation↓, In vivo tumor
volume↓, Radiosensitivity↓
[25, 27, 31, 62–65]
Hsa-mir-29b PDPNd Invasiveness↓ Proliferation↓ Apoptosis↑ [25, 36, 45, 114]
Hsa-mir-32bc Mdm2, TSC1 In vivo tumor volume↓ [24, 45, 78]
Hsa-mir-34aac SIRT1d, c-Met, Notch1/2,
PDGFRAd, Msi1
Viability↓, Proliferation↓, Apoptosis↑,
Invasiveness↓, In vivo tumor volume↓,
Differentiation↑
[67–71]
Hsa-mir-100 ATM Radiosensitivity↑ [115]
Hsa-mir-101b EZH2 Msi1 Angiogenesis↓, Migration↓,
Viability↓, Proliferation↓
[71, 79]
Hsa-mir-124 SNAI2d Proliferation↓, Migration↓, Invasiveness↓,
Stemness↓
[12, 24–27, 35–37, 45, 52, 116, 117]





In vivo tumor volume↓
[22, 24–26, 31, 35, 37, 52, 55, 71–75]
Hsa-mir-128b WEE1 [12, 22, 25, 26, 35, 37, 52]
Hsa-mir-129 [24–27, 101]
Hsa-mir-132 [12, 24–26, 31, 35, 52]
Hsa-mir-135ac STAT6, Smad5, BMPR2 Inhibition causes: In vivo tumor
volume↓, Apoptosis↑
[118]
Hsa-mir-137ac CDK6, Msi1, Cox-2 Proliferation↓, Invasiveness↓,
Migration↓, In vivo tumor volume↓
[25–27, 35, 45, 52, 71, 77]
Hsa-mir-138 Msi1 Proliferation↓ [24, 37, 71]
Hsa-mir-139-5p [12, 25–27, 31]
Hsa-mir-146b-5pc EGFRd Invasiveness↓, Migration↓,
Proliferation↓, In vivo tumor volume↓
[119]
Hsa-mir-149 RAP1B, Wnt-pathway Proliferation↓, Migration↓ [31, 37]
Hsa-mir-153 Bcl-2, Mcl-1, Irs-2 Proliferation↓, Viability↓, Apoptosis↑ [26, 120]
Hsa-mir-181a Bcl-2 Proliferation↓, Apoptosis↑,
Invasiveness↓, Radiosensitivity↑
[22, 37, 121, 122]
Hsa-mir-181b Proliferation↓, Apoptosis↑, Invasiveness↓ [22, 37, 45, 53, 121]
Hsa-mir-181dc Bcl-2, K-Rasd Proliferation↓, Apoptosis↑, In vivo
tumor volume↓
[123]
Hsa-mir-184 Akt2d Apoptosis↑, Invasiveness↓ [30]
Hsa-mir-185 DNMT1 DNA methylation↓ [124]
Hsa-mir-218 IKK-βd Invasiveness↓ [25–27, 125]
Hsa-mir-326bc Notch-1/2, PKM2d Proliferation↓, Apoptosis↑, Viability↓,
Invasiveness↓, In vivo tumor volume↓
[80, 81]
Hsa-mir-483-5pb ERK1d Proliferation↓ [24, 83]
Hsa-mir-491-5pb MMP9d Invasiveness↓ [37, 82]
miRNAs consistently downregulated in glioblastoma. The table presents miRNAs with observed effects upon their upregulation and their validated
targets. The cell lines in which the studies have been performed are presented. Only miRNAs that are investigated in greater than or equal to five studies
and/or have a validated target are included in this table. The cell lines applied in the annotated studies can be found in Supplementary Table 1
aMentioned in the section “MicroRNAs downregulated in Glioblastoma Multiforme”
bMentioned in the section “MicroRNAs Downregulated in Glioblastoma Multiforme with Limited Functional Characterization”
cMicroRNAs whose upregulation is shown to inhibit tumor growth in vivo
d Targets involved in the mesenchymal mode of migration and invasion
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migration and invasion, possibly in part mediated by
lowered levels MMP-2 and MMP-9 [63]. It is evident
that miR-7 is an important suppressor of the MMMI,
and future research could reveal further promising ther-
apeutic characteristics.
miR-34a
The first interesting study investigating miR-34a utilized both
CD133+ and CD133− GBM cells, thus also examining the
connection between the cancer stem cell hypothesis and
miRNA. Here, Li et al. [50] found that forced overexpression
of miR-34a resulted in inhibited proliferation and invasion both
in vitro and in immunodeficient mice. It was found that these
growth inhibitory effects on both CD133+ and CD133− cells
were mediated by targeting the Notch signaling pathway via
Notch1/2 and via c-Met [67]. Later, the group showed that miR-
34a overexpression led to an increase in cell differentiation and
apoptosis in a glioma stem cell culture [68]. The tumor-
suppressive role of miR-34a was confirmed by Luan et al.
who also found that miR-34a levels reflect the status of tumor
suppressor p53, and that miR-34a could activate the p53 signal-
ing cascade of p53 expression independently, possibly through
targeting of SIRT1 [69]. Recently, two new targets of miR-34a
were determined: Musashi1 and platelet-derived growth factor
receptor-α (PDGFRA), last mentioned known to be amplified in
GBM [70, 71]. Interestingly, a negative feedback mechanism
between PDGFRA and miR-34a was discovered, implying that
the underlying cause ofmiR-34a downregulation inGBMmight
be a result of increased PDGF-signaling [70]. Despite an obvi-
ous potential, intracranial delivery of miR-34a in the treatment
of GBM has yet to be attempted.
miR-128
Several papers have reported significant miR-128 repression
in GBM cell lines and tumor samples [22, 24–26, 31, 35, 37,
52, 55, 71–75]. It is capable of suppressing tumor growth,
mediated through numerous direct gene targets in a number of
different cell lines. The first target investigated, Bmi-1, which
normally drives stem cell renewal and glioma growth, was
found to be downregulated upon miR-128 induction [75].
Adding to the antiproliferative effect of miR-128 is the fact
that it mediates the silencing of the transcription factor E2F3a,
an effect that was shown to be reversible by E2F3a restoration
[73, 74]. Papagiannakopoulos et al. found the two growth
factor receptors EGFR and PDGFRA, both typically overex-
pressed in GBM, to be repressed by miR-128 [76]. Other
direct targets of miR-128 include WEE1 [25] and Msi1,
involved in proliferation, and p70S6K1, involved in angio-
genesis [72]. Based on the above-mentioned experimental
evidence, it appears that miR-128 is a good candidate for
repressing GBM growth and invasion.
miR-137
Since its first description in relation to the pathology of
GBM in 2008, miR-137 has been consistently reported as
downregulated and has often been investigated in combina-
tion with other miRNAs, e.g., miR-124 [25–27, 35, 45, 52,
71, 77]. Studies have revealed antiproliferative and anti-
invasive effects upon forced miR-137 overexpression,
mediated through CDK6 [27], Msi1 [71], and Cox-2
[77]. Of significant interest here is the inhibition of
Cox-2, as this enzyme is shown to play a role in cell
proliferation [77].
MicroRNAs Upregulated in Glioblastoma Multiforme
with Limited Functional Characterization
As for the upregulated miRNAs, several specific downregu-
lated miRNAs have been intensively investigated, while
others, e.g., miR-32, miR-101, miR-326, and miR-491-5p,
have received limited attention. Furthermore, mir-181b, mir-
139-5p, mir-132, and mir-129 were found to be consistently
downregulated in greater than or equal to five studies but
remains uninvestigated with respect to functional role in
GBM. miR-32 was found to be downregulated in three
studies and shown to suppress intracranial xenograft
tumor growth, thus improving overall survival rate of
mice. Furthermore, two important p53 inhibitors,
MDM2 and TSC1, were validated as direct targets of
this miRNA [24, 45, 78]. Two studies found that miR-
101 was able to decrease levels of angiogenesis, prolif-
eration, migration, and viability by targeting part of the
Polycomb-group family EZH2 and Msi1 [71, 79]. Low-
ered expression of EZH2 results in a reduction of his-
tone methylation, affecting the expression of several
genes involved in tumor suppression [71, 79].
Until now, only Kefas et al. [80, 81] have investigated
miR-326 expression and function in GBM. In their two
publications, they found that by targeting Notch1/2 and
pyruvate kinase M2 (PKM2), miR-326 was able to decrease
proliferation and invasiveness in a subset of different cell
lines. In addition, they proposed that miR-326 and Notch1
regulate each other in a negative feedback manner [80, 81].
Another miRNA with anti-invasive properties is miR-491-
5p, which is found to inhibit MMP9, a key component in the
degradation of extracellular matrix [82].
The most recently published study on miR-483-5p has
shown that it is decreased in both tumor samples and cell
lines. Induction of miR-483-5p inhibited proliferation of
GBM cells by arrest in the G0/G1 transition. Further veri-
fying these results, was the interesting finding that miR-483-
5p caused silencing of ERK1, known to be an important
factor in several major mitogenic signaling pathways [83].
Clearly, the function of miR-483-5p is interesting with
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respect to its involvement in cell cycle arrest and its role in
gene silencing of key regulatory pathways in tumorigenesis.
MicroRNAs with Disputed Levels of Expression
in Glioblastoma Multiforme
Besides the long list of up- and downregulated miRNAs are
a group of conflicting experimental findings that need fur-
ther resolution in order to define the key regulatory deter-
minants. Throughout the literature review process, a number
of studies could be identified where the expression levels of
miRNAs were disputed (Table 3). In total, 17 miRNAs were
found to be both up- and downregulated. Much of this could
be attributed to the experimental framework of the studies,
different models, and the well-known fact that the tumor
niche is a governing factor with respect to gene regulation
and expression [84, 85]. In the following section, a number
of these disputed miRNAs will be discussed.
miR-145
One of the miRNAs with disputed findings in expression
levels between nonmalignant brain tissue and GBM tumor
samples/cell lines was miR-145 [6, 11, 86]. miR-145 was
reported to be downregulated by Lee et al. [11] who also
found a decrease in proliferation and invasion when induc-
ing overexpression of miR-145. Furthermore, when insert-
ing a miR-145 expression cassette into a HSVtk-expressing
adenoviral vector, an increase in survival was observed
following transmission to mice [11]. These observations
were strengthened by Yang et al. [86] who showed increased
radio- and chemosensitivity accompanied by a decrease in
migration, stemness, and xenograft tumor growth upon
miR-145 overexpression. These effects were found to be
mediated through direct targeting of the two stemness tran-
scription factors Oct4 and Sox2 [86]. However, contradic-
tory to these two studies, Koo et al. [6] reported miR-145 to
be upregulated in a number of highly invasive GBM cell
lines, and that downregulation of miR-145 decreased the
invasive abilities of GBM cells. Interestingly, the group also
found miR-145 to be most upregulated in highly invasive
regions of freshly resected human GBM tumor samples [6].
miR-451
Generating another discrepancy in the literature are two
papers exploring expression levels of miR-451 in GBM cell
lines, finding dissimilar results [87, 88]. Gal et al. found that
miR-451 was overexpressed in CD133− GBM cells, while
Table 3 miRNAs with disputed expression levels and their functional role in GBM









Hsa-mir-19a CTGF Viability↓, Apoptosis↑,
Proliferation↓
[24–26, 30] [34]
Hsa-mir-26b EphA2a Proliferation↓, Invasiveness↓,
Angiogenesis↓
[31] [26, 107]
Hsa-mir-27b WEE1 Proliferation↓, Apoptosis↑,
Invasiveness↓
[126] [25]
Hsa-mir-106a E2F1 Proliferation↓, Apoptosis↑ [24, 26, 35] [45, 127]
Hsa-mir-143 Invasiveness↓ [6] [26]




Invasiveness↓ [6, 86] [11]








Migration↑ [23, 87, 89] [35, 52, 88, 89]
miRNAs found to be both up- and downregulated in GBM and their functional role. The table presents miRNAs, which have been reported with
differential expression levels in GBM between different research groups. Only miRNAs that are investigated in greater than or equal to five studies
and/or have a validated target are included in this table. The effects of upregulation or downregulation and validated targets are presented. The cell
lines applied in the annotated studies can be found in Supplementary Table 1
a Targets involved in the mesenchymal mode of migration and invasion
bMentioned in the section “miRNAs with disputed expression levels”
c miRNAs whose upregulation is shown to inhibit tumor growth in vivo
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Nan et al. found a downregulation of miR-451 in three
GBM cell lines [87, 88]. However, both papers agreed that
transfection with miR-451-mimics significantly decreased
proliferation and viability, thus implying that miR-451 has
tumor-suppressive effects in vitro. A possible explanation
for these contradictory results might exist as presented by
Godlewski et al. [89]. In two key papers, they investigated
the relationship between metabolic stress in GBM cell lines
and the expression of miR-451. Interestingly, they discov-
ered that the cell migratory ability varies, dependent on
glucose availability. Thus, when glucose levels are low,
miR-451 is underexpressed, leading to increased migration
via the AMPK/MAPK-pathway, mediated by direct target-
ing of calcium-binding protein 39 (CAB39) [90, 91].
MicroRNAs and the Mesenchymal Mode of Migration
and Invasion
Epithelial to mesenchymal transition (EMT) is a phenome-
non during which epithelial cells lose many of their
epithelial characteristics and acquire markers and phe-
notypes of mesenchymal cells. EMT facilitates metasta-
sis through increased migration, invasion, intravasation
and/or extravasation [92, 93]. Due to the astrocytic
origin of GBM, a complementary concept called MMMI
is proposed as a valuable notion in the malignant pro-
gression of glioblastoma (inspired by Zhong et al. [5]).
EMT encompasses many known pathways such as the
EGFR, TGF-β, and Wnt-signaling that promote the contin-
uous acquisition of malignant biological features by cancer
cells and contributes to the highly invasive nature of certain
cancers [94]. Essential transcription factors in EMT include
ZEBs (delta-crystalline enhancer binding factors) which,
together with the EMT-promoting transcription factor
TWIST, regulate several of the EMT-associated pathways
and enhance cellular invasion [95]. The ZEB and Twist
proteins are implicated in EMT in several tumor types and
regulate, or are under the regulation of miRNAs, underpin-
ning that miRNAs are important regulators of malignancy
development [93].
MMMI encompasses interaction between GBM cells and
their surrounding extracellular matrix (ECM), through
integrin-attachment and detachment resulting in FAK-
signaling. This prompts several intracellular changes such
as actin filamentation and myosin phosphorylation, which
ultimately enables cell locomotion. Invasive GBM cells
infiltrate the brain parenchyma and escape surgical resection
Fig. 2 Schematic overview of miRNAs involved in the mesenchymal
mode of migration and invasion in glioma. The inhibition of validated
targets (yellow boxes) by specific miRNAs results in either pro-
invasive (red box) or anti-invasive (green box) effects. Red ovals depict
upregulated, oncogenic miRNAs, e.g., miR-10b targets HOXD10,
resulting in increased MMP14 expression and invasion. Blue ovals
depict downregulated tumor suppressor miRNAs in GBM, e.g., miR-
26b targets EphA2, resulting in decreased levels of angiogenesis
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and other local therapeutic modalities, and are considered a
principle reason for tumor recurrence [5]. In the following
section, the concept of MMMI is broadened to include all
cellular processes, related to miRNAs, facilitating invasion
and migration of GBM cells.
It is clear from the literature that a number of miRNAs,
both oncogenic and tumor suppressive, are involved in
MMMI, thus affecting cell migration, cytoskeletal rear-
rangement, invasiveness, and angiogenesis (Fig. 2). This
emphasizes the function of miRNAs as modulators of the
ECM and tumor niche. miR-21, the most investigated
miRNA in the literature, has been shown to be involved in
many aspects regarding MMMI [22, 38, 93]. It is able to
increase the expression and activity levels of a number of
MMPs, facilitate Ras/Raf binding, and induce ERK phos-
phorylation through targeting of known tumor suppressors,
like RECK, TIMP3, ANP32A, and SPRY2, thereby enhanc-
ing the invasive potential of the GBM cells [38, 39, 46, 48].
By inhibiting DAAM1, miR-335 is able to initiate cyto-
skeletal rearrangement and decrease the level of myosin light
chain phosphorylation, which ultimately results in increased
invasion [59]. Similar results have been obtained when ex-
ploring the effects of other known oncogenic miRNAs, such
as miR-10b, miR-30e*, miR-125b, and miR-221 [29, 96–98].
In addition, 16 tumor-suppressive miRNAs (Fig. 2) are
shown to play a role in the inhibition of invasion. For
example, overexpression of miR-7, which targets EGFR
and FAK, reduces the level of invasion in GBM, and dimin-
ishes the expressional levels of MMPs and phosphorylation
of Akt and Erk [63–65]. miR-326 targets PKM2 with a
resulting decrease in ATP levels, which is associated with
less mTOR signaling and less invasion [81]. Furthermore,
interesting results have been obtained regarding miR-491-
5p, which directly targets MMP9 and, therefore, inhibits
migration of GBM cells [82].
Another factor associated with invasion is angiogenesis,
which is also under regulation of miRNAs. In addition to
bringing nutrients to the tumor mass, angiogenesis is also
required for facilitating tumor cell migration [93]. miRNAs,
such asmiR-93 andmiR-205, have been shown to regulate the
level of angiogenesis; miR-93 inhibits integrin-β8 with a
resultant increase in angiogenesis [56], while miR-205, which
targets VEGF-A, has the opposite effect [99]. Given the broad
and very profound involvement of miRNAs in the regulation
of gene expression and extracellular signaling, a focus on the
miRNAs involved in MMMI and ECM dynamics as future
agents, or targets for therapy, would be promising.
Conclusion
In this comprehensive review of 102 papers, we have
attempted to highlight the expression profile of miRNAs
significantly up- or downregulated in GBM and subsequent-
ly focused on a group defined as more novel with respect to
functional characterization. 253 miRNAs were found to be
significantly upregulated, 95 significantly downregulated,
and 17 were disputed with respect to expression levels###;
313 of these miRNAs have yet to be functionally character-
ized, prompting the need for further investigations. The
function of miRNAs encompasses modulation of the ECM
dynamics (Fig. 2) and likewise the miRNA expression can
be influenced by the tumor niche [85]. Hence, the assembly
of a group of miRNAs with disputed results in the levels of
expression highlights the importance of tissue isolation/pro-
cessing, choice of control tissue, and the tumor microenvi-
ronment; all of which are factors that could contribute to
these differences in expression. Even though 365 miRNAs
have been studied with respect to their expression in glioma,
only 21 of them have been investigated with respect to their
function in vivo (Supplementary Table 1). Furthermore, the
15 most studied miRNAs (miR-7, miR-10b, miR-15b, miR-
17, miR-21, miR-23a, miR-25, miR-124, miR-128a, miR-
128b, miR-132, miR-137, miR-195, miR-221, and miR-
222) in GBM were investigated in 62 out of the 102 papers.
The popularity per se of this cohort of well-investigated
miRNAs sets a bias in the literature with respect to the
importance of these miRNAs in glioma initiation, progres-
sion, and invasion. This leaves a large number of miRNAs
that could hold a similar or greater potential in future ther-
apeutics than the highly studied cohort.
Acknowledgments This research was supported by the Department
of Health Science and Technology, Aalborg University. Further thanks
to Spar Nord Fonden, Det Obelske Familiefond, and Harboe Fonden.
Open Access This article is distributed under the terms of the Creative
Commons Attribution License which permits any use, distribution, and
reproduction in any medium, provided the original author(s) and the
source are credited.
References
1. Ohgaki H, Kleihues P (2007) Genetic pathways to primary and
secondary glioblastoma. Am J Pathol 170(5):1445–1453
2. Ohgaki H, Kleihues P (2005) Population-based studies on inci-
dence, survival rates, and genetic alterations in astrocytic and
oligodendroglial gliomas. J Neuropathol Exp Neurol 64(6):479–
489
3. Ohgaki H, Dessen P, Jourde B, Horstmann S, Nishikawa T, Di
Patre P-L, Burkhard C, Schüler D, Probst-Hensch NM, Maiorka
PC, Baeza N, Pisani P, Yonekawa Y, Yasargil MG, Lütolf UM,
Kleihues P (2004) Genetic pathways to glioblastoma: a
population-based study. Cancer Res 64(19):6892–6899
4. Furnari FB, Fenton T, Bachoo RM, Mukasa A, Stommel JM,
Stegh A, Hahn WC, Ligon KL, Louis DN, Brennan C, Chin L,
DePinho RA, Cavenee WK (2007) Malignant astrocytic glioma:
genetics, biology, and paths to treatment. Genes Dev 21
(21):2683–2710
140 Mol Neurobiol (2013) 47:131–144
5. Zhong J, Paul A, Kellie SJ, O’Neill GM (2010) Mesenchymal
migration as a therapeutic target in glioblastoma. J Oncol
2010:430142. doi:10.1155/2010/430142
6. Koo S, Martin GS, Schulz KJ, Ronck M, Toussaint LG (2012)
Serial selection for invasiveness increases expression of miR-
143/miR-145 in glioblastoma cell lines. BMC Cancer 12(1):143
7. Hong B, Wiese B, Bremer M, Heissler HE, Heidenreich F, Krauss
JK and Nakamura M (2012) Multiple microsurgical resections for
repeated recurrence of glioblastoma multiforme. Am J Clin Oncol
8. Becker KP, Yu J (2012) Status quo–standard-of-care medical and
radiation therapy for glioblastoma. Cancer J 18(1):12–19
9. Mohyeldin A, Chiocca EA (2012) Gene and viral therapy for
glioblastoma: a review of clinical trials and future directions.
Cancer J 18(1):82–88
10. Kostron H (2010) Photodynamic diagnosis and therapy and the
brain. Methods Mol Biol 635:261–280
11. Lee S-J, Kim S-J, Seo H-H, Shin S-P, Kim D, Park C-S, Kim K-T,
Kim Y-H, Jeong J-S, Kim I-H (2012) Over-expression of miR-
145 enhances the effectiveness of HSVtk gene therapy for malig-
nant glioma. Cancer Lett 320(1):72–80
12. Skalsky RL, Cullen BR (2011) Reduced expression of brain-
enriched microRNAs in glioblastomas permits targeted regulation
of a cell death gene. PLoS One 6(9):e24248
13. Ohka F, Natsume A, Wakabayashi T (2012) Current trends in
targeted therapies for glioblastoma multiforme. Neurol Res Int
2012:878425. doi:10.1155/2012/878425
14. Winter J, Jung S, Keller S, Gregory RI, Diederichs S (2009)
Many roads to maturity: microRNA biogenesis pathways and
their regulation. Nat Cell Biol 11(3):228–234
15. Yi R, Qin Y, Macara IG, Cullen BR (2003) Exportin-5 mediates
the nuclear export of pre-microRNAs and short hairpin RNAs.
Genes Dev 17(24):3011–3016
16. Kawamata T, Yoda M, Tomari Y (2011) Multilayer checkpoints
for microRNA authenticity during RISC assembly. EMBO Rep
12(9):944–949
17. Winter J, Diederichs S (2011) MicroRNA biogenesis and cancer.
Methods Mol Biol 676:3–22
18. Rana TM (2007) Illuminating the silence: understanding the struc-
ture and function of small RNAs. Nat RevMol Cell Biol 8(1):23–36
19. Stoorvogel W (2012) Functional transfer of microRNA by exo-
somes. Blood 119(3):646–648
20. Chen X, Liang H, Zhang J, Zen K, Zhang C-Y (2012) Horizontal
transfer of microRNAs: molecular mechanisms and clinical appli-
cations. Protein Cell 3(1):28–37
21. Chan JA, Krichevsky AM, Kosik KS (2005) MicroRNA-21 is an
antiapoptotic factor in human glioblastoma cells. Cancer Res 65
(14):6029–6033
22. Ciafrè SA, Galardi S, Mangiola A, Ferracin M, Liu CG, Sabatino
G, Negrini M, Maira G, Croce CM, Farace MG (2005) Extensive
modulation of a set of microRNAs in primary glioblastoma.
Biochem Biophys Res Commun 334(4):1351–1358
23. Huse JT, Brennan C, Hambardzumyan D, Wee B, Pena J,
Rouhanifard SH, Sohn-Lee C, le Sage C, Agami R, Tuschl
T, Holland EC (2009) The PTEN-regulating microRNA miR-
26a is amplified in high-grade glioma and facilitates glioma-
genesis in vivo. Genes Dev 23(11):1327–1337
24. Rao SAM, Santosh V, Somasundaram K (2010) Genome-wide
expression profiling identifies deregulated miRNAs in malignant
astrocytoma. Mod Pathol 23(10):1404–1417
25. Wuchty S, Arjona D, Li A, Kotliarov Y, Walling J, Ahn S, Zhang
A, Maric D, Anolik R, Zenklusen JC, Fine HA (2011) Prediction
of associations between microRNAs and gene expression in
glioma biology. PLoS One 6(2):e14681
26. Lavon I, Zrihan D, Granit A, Einstein O, Fainstein N, Cohen MA,
Cohen MA, Zelikovitch B, Shoshan Y, Spektor S, Reubinoff BE,
Felig Y, Gerlitz O, Ben-Hur T, Smith Y, Siegal T (2010) Gliomas
display a microRNA expression profile reminiscent of neural
precursor cells. Neuro-Oncology 12(5):422–433
27. Silber J, Lim DA, Petritsch C, Persson AI, Maunakea AK, Yu M,
Vandenberg SR, Ginzinger DG, James CD, Costello JF, Bergers
G, Weiss WA, Alvarez-Buylla A, Hodgson JG (2008) miR-124
and miR-137 inhibit proliferation of glioblastoma multiforme
cells and induce differentiation of brain tumor stem cells. BMC
Med 6:14
28. Sasayama T, Nishihara M, Kondoh T, Hosoda K, Kohmura E
(2009) MicroRNA-10b is overexpressed in malignant glioma and
associated with tumor invasive factors, uPAR and RhoC. Int J
Cancer 125(6):1407–1413
29. Sun L, Yan W, Wang Y, Sun G, Luo H, Zhang J, Wang X, You Y,
Yang Z, Liu N (2011) MicroRNA-10b induces glioma cell inva-
sion by modulating MMP-14 and uPAR expression via HOXD10.
Brain Res 1389:9–18
30. Malzkorn B, Wolter M, Liesenberg F, Grzendowski M, Stühler K,
Meyer HE, Reifenberger G (2010) Identification and functional
characterization of microRNAs involved in the malignant pro-
gression of gliomas. Brain Pathol 20(3):539–550
31. Lages E, Guttin A, Atifi El M, Ramus C, Ipas H, Dupré I, Rolland
D, Salon C, Godfraind C, deFraipont F, Dhobb M, Pelletier L,
Wion D, Gay E, Berger F, Issartel J-P (2011) MicroRNA and
target protein patterns reveal physiopathological features of glio-
ma subtypes. PLoS One 6(5):e20600
32. Schraivogel D, Weinmann L, Beier D, Tabatabai G, Eichner A,
Zhu JY, Anton M, Sixt M, Weller M, Beier CP, Meister G (2011)
CAMTA1 is a novel tumour suppressor regulated by miR-9/9* in
glioblastoma stem cells. EMBO J 30(20):4309–4322
33. Dews M, Fox JL, Hultine S, Sundaram P, Wang W, Liu YY, Furth
E, Enders GH, El-Deiry W, Schelter JM, Cleary MA, Thomas-
Tikhonenko A (2010) The myc-miR-17 92 axis blunts TGF{beta}
signaling and production of multiple TGF{beta}-dependent antian-
giogenic factors. Cancer Res 70(20):8233–8246
34. Ernst A, Campos B, Meier J, Devens F, Liesenberg F, Wolter M,
Reifenberger G, Herold-Mende C, Lichter P, Radlwimmer B
(2010) De-repression of CTGF via the miR-17-92 cluster upon
differentiation of human glioblastoma spheroid cultures. Onco-
gene 29(23):3411–3422
35. Zhou X, Ren Y, Moore L, Mei M, You Y, Xu P, Wang B, Wang G,
Jia Z, Pu P, Zhang W, Kang C (2010) Downregulation of miR-21
inhibits EGFR pathway and suppresses the growth of human
glioblastoma cells independent of PTEN status. Lab Invest 90
(2):144–155
36. Dong H, Luo L, Hong S, Siu H, Xiao Y, Jin L, Chen R, Xiong M
(2010) Integrated analysis of mutations, miRNA and mRNA
expression in glioblastoma. BMC Syst Biol 4:163
37. Li D, Chen P, Li X-Y, Zhang L-Y, Xiong W, Zhou M, Xiao L,
Zeng F, Li X-L, Wu M-H, Li G-Y (2011) Grade-specific expres-
sion profiles of miRNAs/mRNAs and docking study in human
grade I-III astrocytomas. OMICS 15(10):673–682
38. Gabriely G, Würdinger T, Kesari S, Esau CC, Burchard J, Linsley
PS, Krichevsky AM (2008) MicroRNA 21 promotes glioma
invasion by targeting matrix metalloproteinase regulators. Mol
Cell Biol 28(17):5369–5380
39. Schramedei K, Mörbt N, Pfeifer G, Läuter J, Rosolowski M,
Tomm JM, von Bergen M, Horn F, Brocke-Heidrich K (2011)
MicroRNA-21 targets tumor suppressor genes ANP32A and
SMARCA4. Oncogene 30(26):2975–2985
40. Zhou X, Zhang J, Jia Q, Ren Y, Wang Y, Shi L, Liu N, Wang G, Pu
P, You Y, Kang C (2010) Reduction of miR-21 induces glioma cell
apoptosis via activating caspase 9 and 3. Oncol Rep 24(1):195–201
41. Li Y, Zhao S, Zhen Y, Li Q, Teng L, Asai A, Kawamoto K (2011)
A miR-21 inhibitor enhances apoptosis and reduces G(2)-M
accumulation induced by ionizing radiation in human glioblasto-
ma U251 cells. Brain Tumor Pathol 28(3):209–214
Mol Neurobiol (2013) 47:131–144 141
42. Papagiannakopoulos T, Shapiro A, Kosik KS (2008) MicroRNA-
21 targets a network of key tumor-suppressive pathways in glio-
blastoma cells. Cancer Res 68(19):8164–8172
43. Corsten MF, Miranda R, Kasmieh R, Krichevsky AM, Weissleder
R, Shah K (2007) MicroRNA-21 knockdown disrupts glioma
growth in vivo and displays synergistic cytotoxicity with neural
precursor cell delivered S-TRAIL in human gliomas. Cancer Res
67(19):8994–9000
44. Shi L, Chen J, Yang J, Pan T, Zhang S, Wang Z (2010) MiR-21
protected human glioblastoma U87MG cells from chemothera-
peutic drug temozolomide induced apoptosis by decreasing Bax/
Bcl-2 ratio and caspase-3 activity. Brain Res 1352:255–264
45. Zhi F, Chen X, Wang S, Xia X, Shi Y, Guan W, Shao N, Qu H,
Yang C, Zhang Y, Wang Q, Wang R, Zen K, Zhang C-Y, Zhang J,
Yang Y (2010) The use of hsa-miR-21, hsa-miR-181b and hsa-
miR-106a as prognostic indicators of astrocytoma. Eur J Cancer
46(9):1640–1649
46. Kwak H-J, Kim Y-J, Chun K-R, Woo YM, Park S-J, Jeong J-A,
Jo SH, Kim TH, Min HS, Chae JS, Choi E-J, Kim G, Shin S-H,
Gwak H-S, Kim S-K, Hong E-K, Lee G-K, Choi K-H, Kim JH,
Yoo H, Park JB, Lee S-H (2011) Downregulation of Spry2 by
miR-21 triggers malignancy in human gliomas. Oncogene 30
(21):2433–2442
47. Ren Y, Zhou X, Mei M, Yuan X-B, Han L, Wang GX, Jia Z-F, Xu
P, Pu P-Y, Kang C-S (2010) MicroRNA-21 inhibitor sensitizes
human glioblastoma cells U251 (PTEN-mutant) and LN229
(PTEN-wild type) to taxol. BMC Cancer 10:27
48. Ren Y, Kang C-S, Yuan X-B, Zhou X, Xu P, Han L, Wang GX,
Jia Z, Zhong Y, Yu S, Sheng J, Pu P-Y (2010) Co-delivery of as-
miR-21 and 5-FU by poly(amidoamine) dendrimer attenuates
human glioma cell growth in vitro. J Biomater Sci Polym Ed 21
(3):303–314
49. Chaudhry MA, Sachdeva H, Omaruddin RA (2010) Radiation-
induced micro-RNA modulation in glioblastoma cells differing in
DNA-repair pathways. DNA Cell Biol 29(9):553–561
50. Li Y, Li W, Yang Y, Lu Y, He C, Hu G, Liu H, Chen J, He J, Yu H
(2009) MicroRNA-21 targets LRRFIP1 and contributes to VM-
26 resistance in glioblastoma multiforme. Brain Res 1286:13–18
51. Gaur AB, Holbeck SL, Colburn NH, Israel MA (2011) Down-
regulation of Pdcd4 by mir-21 facilitates glioblastoma prolifera-
tion in vivo. Neuro-Oncology 13(6):580–590
52. Zhang C, Han L, Zhang A, Yang W, Zhou X, Pu P, Du Y, Zeng H,
Kang C (2010) Global changes of mRNA expression reveals an
increased activity of the interferon-induced signal transducer and
activator of transcription (STAT) pathway by repression of miR-
221/222 in glioblastoma U251 cells. Int J Oncol 36(6):1503–1512
53. Conti A, Aguennouz M, La Torre D, Tomasello C, Cardali S,
Angileri FF, Maio F, Cama A, Germanò A, Vita G, Tomasello F
(2009) miR-21 and 221 upregulation and miR-181b downregu-
lation in human grade II-IV astrocytic tumors. J Neurooncol 93
(3):325–332
54. Guan Y, Mizoguchi M, Yoshimoto K, Hata N, Shono T, Suzuki
SO, Araki Y, Kuga D, Nakamizo A, Amano T, Ma X, Hayashi K,
Sasaki T (2010) MiRNA-196 is upregulated in glioblastoma but
not in anaplastic astrocytoma and has prognostic significance.
Clin Cancer Res 16(16):4289–4297
55. Lakomy R, Sana J, Hankeova S, Fadrus P, Kren L, Lzicarova E,
Svoboda M, Dolezelova H, Smrcka M, Vyzula R, Michalek J,
Hajduch M, Slaby O (2011) MiR-195, miR-196b, miR-181c,
miR-21 expression levels and O-6-methylguanine-DNA methyl-
transferase methylation status are associated with clinical out-
come in glioblastoma patients. Cancer Sci 102(12):2186–2190
56. Fang L, Deng Z, Shatseva T, Yang J, Peng C, Du WW, Yee AJ,
Ang LC, He C, Shan SW, Yang BB (2011) MicroRNA miR-93
promotes tumor growth and angiogenesis by targeting integrin-
β8. Oncogene 30(7):806–821
57. Dong H, Siu H, Luo L, Fang X, Jin L, Xiong M (2010) Investi-
gation gene and microRNA expression in glioblastoma. BMC
Genomics 11(Suppl 3):S16
58. Silber J, James CD, Hodgson JG (2009) microRNAs in gliomas:
small regulators of a big problem. Neuromol Med 11(3):208–222
59. Shu M, Zheng X, Wu S, Lu H, Leng T, Zhu W, Zhou Y, Ou Y, Lin
X, Lin Y, Xu D, Zhou Y, Yan G (2011) Targeting oncogenic miR-
335 inhibits growth and invasion of malignant astrocytoma cells.
Mol Cancer 10:59
60. Tang H, Liu X, Wang Z, She X, Zeng X, Deng M, Liao Q, Guo
X, Wang R, Li X, Zeng F, Wu M, Li G (2011) Interaction of hsa-
miR-381 and glioma suppressor LRRC4 is involved in glioma
growth. Brain Res 1390:21–32
61. Shu M, Zhou Y, Zhu W, Zhang H, Wu S, Chen J, Yan G (2012)
MicroRNA 335 is required for differentiation of malignant glio-
ma cells induced by activation of cAMP/protein kinase A path-
way. Mol Pharmacol 81(3):292–298
62. Leber MF, Bossow S, Leonard VHJ, Zaoui K, Grossardt C,
FrenzkeM,Miest T, Sawall S, Cattaneo R, von Kalle C, Ungerechts
G (2011) MicroRNA-sensitive oncolytic measles viruses for
cancer-specific vector tropism. Mol Ther 19(6):1097–1106
63. Wu D-G, Wang Y-Y, Fan L-G, Luo H, Han B, Sun L-H, Wang X-F,
Zhang J-X, Cao L,Wang X-R, YouY-P, Liu N (2011)MicroRNA-7
regulates glioblastoma cell invasion via targeting focal adhesion
kinase expression. Chin Med J 124(17):2616–2621
64. Lu ZJ, Liu SY, Yao YQ, Zhou YJ, Zhang S, Dai L, Tian HW,
Zhou Y, Deng HX, Yang JL, Luo F (2011) The effect of miR-7 on
behavior and global protein expression in glioma cell lines.
Electrophoresis 32(24):3612–3620
65. Kefas B, Godlewski J, Comeau L, Li Y, Abounader R, Hawkinson
M, Lee J, Fine H, Chiocca EA, Lawler S, Purow B (2008)
microRNA-7 inhibits the epidermal growth factor receptor and the
Akt pathway and is down-regulated in glioblastoma. Cancer Res 68
(10):3566–3572
66. Parsons DW, Jones S, Zhang X, Lin JC-H, Leary RJ, Angenendt
P, Mankoo P, Carter H, Siu I-M, Gallia GL, Olivi A, McLendon
R, Rasheed BA, Keir S, Nikolskaya T, Nikolsky Y, Busam DA,
Tekleab H, Diaz LA, Hartigan J, Smith DR, Strausberg RL, Marie
SKN, Shinjo SMO, Yan H, Riggins GJ, Bigner DD, Karchin R,
Papadopoulos N, Parmigiani G, Vogelstein B, Velculescu VE,
Kinzler KW (2008) An integrated genomic analysis of human
glioblastoma multiforme. Science 321(5897):1807–1812
67. Li Y, Guessous F, Zhang Y, Dipierro C, Kefas B, Johnson E,
Marcinkiewicz L, Jiang J, Yang Y, Schmittgen TD, Lopes B,
Schiff D, Purow B, Abounader R (2009) MicroRNA-34a inhibits
glioblastoma growth by targeting multiple oncogenes. Cancer
Res 69(19):7569–7576
68. Guessous F, Zhang Y, Kofman A, Catania A, Li Y, Schiff D, Purow
B, Abounader R (2010) microRNA-34a is tumor suppressive in
brain tumors and glioma stem cells. Cell Cycle 9(6):1031–1036
69. Luan S, Sun L, Huang F (2010) MicroRNA-34a: a novel tumor
suppressor in p53-mutant glioma cell line U251. Arch Med Res
41(2):67–74
70. Silber J, Jacobsen A, Ozawa T, Harinath G, Pedraza A, Sander C,
Holland EC, Huse JT (2012) miR-34a repression in proneural
malignant gliomas upregulates expression of its target PDGFRA
and Promotes tumorigenesis. PLoS One 7(3):e33844
71. Vo DT, Qiao M, Smith AD, Burns SC, Brenner AJ and Penalva
LOF (2011) The oncogenic RNA-binding protein Musashi1 is
regulated by tumor suppressor miRNAs. RNA Biol 8(5)
72. Shi Z-M, Wang J, Yan Z, You Y-P, Li C-Y, Qian X, Yin Y, Zhao P,
Wang Y-Y, Wang X-F, Li M-N, Liu L-Z, Liu N, Jiang B-H (2012)
MiR-128 inhibits tumor growth and angiogenesis by targeting
p70S6K1. PLoS One 7(3):e32709
73. Cui JG, Zhao Y, Sethi P, Li YY, Mahta A, Culicchia F, Lukiw WJ
(2010) Micro-RNA-128 (miRNA-128) down-regulation in
142 Mol Neurobiol (2013) 47:131–144
glioblastoma targets ARP5 (ANGPTL6), Bmi-1 and E2F-3a, key
regulators of brain cell proliferation. J Neurooncol 98(3):297–304
74. Zhang Y, Chao T, Li R, Liu W, Chen Y, Yan X, Gong Y, Yin B,
Liu W, Qiang B, Zhao J, Yuan J, Peng X (2009) MicroRNA-128
inhibits glioma cells proliferation by targeting transcription factor
E2F3a. J Mol Med 87(1):43–51
75. Godlewski J, Nowicki MO, Bronisz A, Williams S, Otsuki A,
Nuovo G, Raychaudhury A, Newton HB, Chiocca EA, Lawler S
(2008) Targeting of the Bmi-1 oncogene/stem cell renewal factor
by microRNA-128 inhibits glioma proliferation and self-renewal.
Cancer Res 68(22):9125–9130
76. Papagiannakopoulos T, Friedmann-Morvinski D, Neveu P, Dugas
JC, Gill RM, Huillard E, Liu C, Zong H, Rowitch DH, Barres
BA, Verma IM, Kosik KS (2012) Pro-neural miR-128 is a glioma
tumor suppressor that targets mitogenic kinases. Oncogene 31
(15):1884–1895
77. Chen L, Wang X, Wang H, Li Y, Yan W, Han L, Zhang K, Zhang
J, Wang Y, Feng Y, Pu P, Jiang T, Kang C and Jiang C (2012)
miR-137 is frequently down-regulated in glioblastoma and is a
negative regulator of Cox-2. Eur J Cancer
78. Suh S-S, Yoo JY, Nuovo GJ, Jeon Y-J, Kim S, Lee TJ, Kim T,
Bakàcs A, Alder H, Kaur B, Aqeilan RI, Pichiorri F, Croce CM
(2012) MicroRNAs/TP53 feedback circuitry in glioblastoma mul-
tiforme. Proc Natl Acad Sci U S A 109(14):5316–5321
79. Smits M, Nilsson J, Mir SE, van der Stoop PM, Hulleman E,
Niers JM, de Witt Hamer PC, Marquez VE, Cloos J, Krichevsky
AM, Noske DP, Tannous BA, Würdinger T (2010) miR-101 is
down-regulated in glioblastoma resulting in EZH2-induced pro-
liferation, migration, and angiogenesis. Oncotarget 1(8):710–720
80. Kefas B, Comeau L, Floyd DH, Seleverstov O, Godlewski J,
Schmittgen T, Jiang J, diPierro CG, Li Y, Chiocca EA, Lee J, Fine
H, Abounader R, Lawler S, Purow B (2009) The neuronal micro-
RNA miR-326 acts in a feedback loop with notch and has
therapeutic potential against brain tumors. J Neurosci 29
(48):15161–15168
81. Kefas B, Comeau L, Erdle N, Montgomery E, Amos S, Purow B
(2010) Pyruvate kinase M2 is a target of the tumor-suppressive
microRNA-326 and regulates the survival of glioma cells. Neuro-
Oncology 12(11):1102–1112
82. Yan W, Zhang W, Sun L, Liu Y, You G, Wang Y, Kang C, You Y,
Jiang T (2011) Identification of MMP-9 specific microRNA
expression profile as potential targets of anti-invasion therapy in
glioblastoma multiforme. Brain Res 1411:108–115
83. Wang L, Shi M, Hou S, Ding B, Liu L, Ji X, Zhang J and Deng Y
(2012) MiR-483-5p suppresses the proliferation of glioma cells
via directly targeting ERK1. FEBS Lett
84. Seidel S, Garvalov BK, Wirta V, von Stechow L, Schänzer A,
Meletis K, Wolter M, Sommerlad D, Henze A-T, Nistér M,
Reifenberger G, Lundeberg J, Frisén J, Acker T (2010) A hypoxic
niche regulates glioblastoma stem cells through hypoxia induc-
ible factor 2 alpha. Brain 133(Pt 4):983–995
85. Lu P, Weaver VM, Werb Z (2012) The extracellular matrix: a
dynamic niche in cancer progression. J Cell Biol 196(4):395–406
86. Yang Y-P, Chien Y, Chiou G-Y, Cherng J-Y, Wang M-L, Lo W-L,
Chang Y-L, Huang P-I, Chen Y-W, Shih Y-H, Chen M-T, Chiou
S-H (2012) Inhibition of cancer stem cell-like properties and
reduced chemoradioresistance of glioblastoma using micro-
RNA145 with cationic polyurethane-short branch PEI. Biomate-
rials 33(5):1462–1476
87. Gal H, Pandi G, Kanner AA, Ram Z, Lithwick-Yanai G, Amariglio
N, Rechavi G, Givol D (2008) MIR-451 and Imatinib mesylate
inhibit tumor growth of Glioblastoma stem cells. Biochem Biophys
Res Commun 376(1):86–90
88. Nan Y, Han L, Zhang A, Wang G, Jia Z, Yang Y, Yue X, Pu P,
Zhong Y, Kang C (2010) MiRNA-451 plays a role as tumor
suppressor in human glioma cells. Brain Res 1359:14–21
89. Godlewski J, Nowicki MO, Bronisz A, Nuovo G, Palatini J, De
Lay M, Van Brocklyn J, Ostrowski MC, Chiocca EA, Lawler SE
(2010) MicroRNA-451 regulates LKB1/AMPK signaling and
allows adaptation to metabolic stress in glioma cells. Mol Cell
37(5):620–632
90. Godlewski J, Bronisz A, Nowicki MO, Chiocca EA, Lawler S
(2010) microRNA-451: A conditional switch controlling glioma
cell proliferation and migration. Cell Cycle 9(14):2742–2748
91. Godlewski J, Newton HB, Chiocca EA, Lawler SE (2010) Micro-
RNAs and glioblastoma; the stem cell connection. Cell Death
Differ 17(2):221–228
92. Nieto MA and Cano A (2012) The epithelial-mesenchymal tran-
sition under control: Global programs to regulate epithelial plas-
ticity. Semin Cancer Biol
93. Bracken CP, Gregory PA, Khew-Goodall Y, Goodall GJ (2009)
The role of microRNAs in metastasis and epithelial-mesenchymal
transition. Cell Mol Life Sci 66(10):1682–1699
94. Jin X, Jeon H-Y, Joo KM, Kim J-K, Jin J, Kim SH, Kang BG,
Beck S, Lee SJ, Kim JK, Park A-K, Park W-Y, Choi Y-J, Nam D-
H, Kim H (2011) Frizzled 4 regulates stemness and invasiveness
of migrating glioma cells established by serial intracranial trans-
plantation. Cancer Res 71(8):3066–3075
95. Mikheeva SA, Mikheev AM, Petit A, Beyer R, Oxford RG,
Khorasani L, Maxwell J-P, Glackin CA, Wakimoto H, González-
Herrero I, Sánchez-García I, Silber JR, Horner PJ, Rostomily RC
(2010) TWIST1 promotes invasion through mesenchymal change
in human glioblastoma. Mol Cancer 9:194
96. Jiang L, Lin C, Song L, Wu J, Chen B, Ying Z, Fang L, Yan X,
He M, Li J, Li M (2012) MicroRNA-30e* promotes human
glioma cell invasiveness in an orthotopic xenotransplantation
model by disrupting the NF-κB/IκBα negative feedback loop. J
Clin Invest 122(1):33–47
97. Wan Y, Fei X-F, Wang Z-M, Jiang D-Y, Chen H-C, Yang J, Shi L
and Huang Q (2012) Expression of miRNA-125b in the new,
highly invasive glioma stem cell and progenitor cell line SU3.
Chin J Cancer
98. Zhang J, Han L, Ge Y, Zhou X, Zhang A, Zhang C, Zhong Y, You
Y, Pu P, Kang C (2010) miR-221/222 promote malignant pro-
gression of glioma through activation of the Akt pathway. Int J
Oncol 36(4):913–920
99. Yue X, Wang P, Xu J, Zhu Y, Sun G, Pang Q, Tao R (2012)
MicroRNA-205 functions as a tumor suppressor in human glio-
blastoma cells by targeting VEGF-A. Oncol Rep 27(4):1200–
1206
100. Xia H, Qi Y, Ng SS, Chen X, Chen S, Fang M, Li D, Zhao Y, Ge
R, Li G, Chen Y, He M-L, Kung H-F, Lai L, Lin MC (2009)
MicroRNA-15b regulates cell cycle progression by targeting
cyclins in glioma cells. Biochem Biophys Res Commun 380
(2):205–210
101. Birks DK, Barton VN, Donson AM, Handler MH, Vibhakar R,
Foreman NK (2011) Survey of MicroRNA expression in pediatric
brain tumors. Pediatr Blood Cancer 56(2):211–216
102. Xia H-F, He T-Z, Liu C-M, Cui Y, Song P-P, Jin X-H, Ma X
(2009) MiR-125b expression affects the proliferation and apopto-
sis of human glioma cells by targeting Bmf. Cell Physiol Bio-
chem 23(4–6):347–358
103. Shi L, Zhang J, Pan T, Zhou J, Gong W, Liu N, Fu Z, You Y
(2010) MiR-125b is critical for the suppression of human U251
glioma stem cell proliferation. Brain Res 1312:120–126
104. Mei J, Bachoo R, Zhang C-L (2011) MicroRNA-146a inhibits
glioma development by targeting Notch1. Cell Mol Biol 31
(17):3584–3592
105. Meng W, Jiang L, Lu L, Hu H, Yu H, Ding D, Xiao K, Zheng W,
Guo H and MaW (2012) Anti-miR-155 oligonucleotide enhances
chemosensitivity of U251 cell to taxol by inducing apoptosis.
Cell Biol Int
Mol Neurobiol (2013) 47:131–144 143
106. Jiang L, Mao P, Song L,Wu J, Huang J, Lin C, Yuan J, Qu L, Cheng
S-Y, Li J (2010) miR-182 as a prognostic marker for glioma pro-
gression and patient survival. Am J Pathol 177(1):29–38
107. Wu N, Zhao X, Liu M, Liu H, Yao W, Zhang Y, Cao S, Lin X
(2011) Role of microRNA-26b in glioma development and its
mediated regulation on EphA2. PLoS One 6(1):e16264
108. Lu X, Zhao P, Zhang C, Fu Z, Chen Y, Lu A, Liu N, You Y, Pu P,
Kang C (2009) Analysis of miR-221 and p27 expression in
human gliomas. Mol Med Rep 2(4):651–656
109. Zhang C-Z, Zhang J-X, Zhang A-L, Shi Z-D, Han L, Jia Z-F,
Yang W-D, Wang GX, Jiang T, You Y-P, Pu P-Y, Cheng J-Q,
Kang C-S (2010) MiR-221 and miR-222 target PUMA to induce
cell survival in glioblastoma. Mol Cancer 9:229
110. Lukiw WJ, Cui JG, Li YY, Culicchia F (2008) Up-regulation of
micro-RNA-221 (miRNA-221; chr Xp11.3) and caspase-3 accom-
panies down-regulation of the survivin-1 homolog BIRC1 (NAIP)
in glioblastoma multiforme (GBM). J Neurooncol 91(1):27–32
111. Medina R, Zaidi SK, Liu C-G, Stein JL, vanWijnen AJ, Croce CM,
Stein GS (2008) MicroRNAs 221 and 222 bypass quiescence and
compromise cell survival. Cancer Res 68(8):2773–2780
112. Quintavalle C, Garofalo M, Zanca C, Romano G, Iaboni M, del
Basso De Caro M, Martinez-Montero JC, Incoronato M, Nuovo
G, Croce CM, Condorelli G (2011) miR-221/222 overexpession
in human glioblastoma increases invasiveness by targeting the
protein phosphate PTPμ. Oncogene 31(7):858–868
113. Wang X, Han L, Zhang A, Wang G, Jia Z, Yang Y, Yue X, Pu P,
Shen C, Kang C (2011) Adenovirus-mediated shRNAs for co-
repression of miR-221 and miR-222 expression and function in
glioblastoma cells. Oncol Rep 25(1):97–105
114. Cortez MA, Nicoloso MS, Shimizu M, Rossi S, Gopisetty G,
Molina JR, Carlotti C, Tirapelli D, Neder L, Brassesco MS,
Scrideli CA, Tone LG, Georgescu M-M, Zhang W, Puduvalli V,
Calin GA (2010) miR-29b and miR-125a regulate podoplanin
and suppress invasion in glioblastoma. Genes Chromosom Can-
cer 49(11):981–990
115. Ng WL, Yan D, Zhang X, Mo Y-Y, Wang Y (2010) Over-
expression of miR-100 is responsible for the low-expression of
ATM in the human glioma cell line: M059J. DNA Repair (Amst)
9(11):1170–1175
116. Fowler A, Thomson D, Giles K, Maleki S, Mreich E, Wheeler H,
Leedman P, Biggs M, Cook R, Little N, Robinson B, McDonald
K (2011) miR-124a is frequently down-regulated in glioblastoma
and is involved in migration and invasion. Eur J Cancer 47
(6):953–963
117. Xia H, Cheung WKC, Ng SS, Jiang X, Jiang S, Sze J, Leung
GKK, Lu G, Chan DTM, Bian X-W, Kung H-F, Poon WS, Lin
MC (2012) Loss of Brain-enriched miR-124 MicroRNA enhan-
ces stem-like traits and invasiveness of glioma cells. J Biol Chem
287(13):9962–9971
118. Wu S, Lin Y, Xu D, Chen J, Shu M, Zhou Y, Zhu W, Su X, Zhou
Y, Qiu P and Yan G (2011) MiR-135a functions as a selective
killer of malignant glioma. Oncogene
119. Katakowski M, Zheng X, Jiang F, Rogers T, Szalad A, Chopp M
(2010) MiR-146b-5p suppresses EGFR expression and reduces in
vitro migration and invasion of glioma. Cancer Invest 28
(10):1024–1030
120. Xu J, Liao X, Wong C (2010) Downregulations of B-cell lym-
phoma 2 and myeloid cell leukemia sequence 1 by microRNA
153 induce apoptosis in a glioblastoma cell line DBTRG-05MG.
Int J Cancer 126(4):1029–1035
121. Slaby O, Lakomy R, Fadrus P, Hrstka R, Kren L, Lzicarova E,
Smrcka M, Svoboda M, Dolezalova H, Novakova J, Valik D,
Vyzula R, Michalek J (2010) MicroRNA-181 family predicts
response to concomitant chemoradiotherapy with temozolomide
in glioblastoma patients. Neoplasma 57(3):264–269
122. Chen G, Zhu W, Shi D, Lv L, Zhang C, Liu P, Hu W (2010)
MicroRNA-181a sensitizes human malignant glioma U87MG
cells to radiation by targeting Bcl-2. Oncol Rep 23(4):997–
1003
123. Wang X-F, Shi Z-M, Wang X-R, Cao L, Wang Y-Y, Zhang J-X,
Yin Y, Luo H, Kang C-S, Liu N, Jiang T, You Y-P (2012) MiR-
181d acts as a tumor suppressor in glioma by targeting K-ras and
Bcl-2. J Cancer Res Clin Oncol 138(4):573–584
124. Zhang Z, Tang H, Wang Z, Zhang B, Liu W, Lu H, Xiao L, Liu X,
Wang R, Li X, Wu M, Li G (2011) MiR-185 targets the DNA
methyltransferases 1 and regulates global DNA methylation in
human glioma. Mol Cancer 10:124
125. Song L, Huang Q, Chen K, Liu L, Lin C, Dai T, Yu C, Wu Z, Li J
(2010) miR-218 inhibits the invasive ability of glioma cells by
direct downregulation of IKK-β. Biochem Biophys Res Commun
402(1):135–140
126. Chen L, Li H, Han L, Zhang K, Wang G, Wang Y, Liu Y, Zheng
Y, Jiang T, Pu P, Jiang C, Kang C (2011) Expression and function
of miR-27b in human glioma. Oncol Rep 26(6):1617–1621
127. Yang G, Zhang R, Chen X, Mu Y, Ai J, Shi C, Liu Y, Shi C, Sun
L, Rainov NG, Li H, Yang B, Zhao S (2011) MiR-106a inhibits
glioma cell growth by targeting E2F1 independent of p53 status. J
Mol Med 89(10):1037–1050
144 Mol Neurobiol (2013) 47:131–144
